Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | DHODH | Q02127 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859453 | 0.92 | ALDH1A1 (0.71) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL7154380 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL5969797 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL21766236 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL600235 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL5970025 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL5969969 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL6390944 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL5969898 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL18997641 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRDHODHL3MBTL1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885TSHR 3836/4885DHODH 289/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 281/4885TSHR 3785/4885DHODH 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.